Investors & Media

News Release Details

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference

January 4, 2022 at 5:00 PM EST

BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10th at 7:00 a.m. Eastern Time.

The virtual session may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit

Investor Relations & Media Inquiries
Aron Feingold

Source: Sangamo Therapeutics, Inc.